Xuebin Qin obtained his M.D., M.S., and Ph.D. degrees from Wannan Medical College (1986), Tongji Medical University (1991), and Peking Union Medical College and Chinese Academy of Medical Sciences (1996), China, respectively. Currently, he serves as an Assistant Professor of medicine at Harvard Medical School (HMS). His group in the Laboratory for Translational Research (LTR) at HMS has been unraveling the cascade of biochemical reactions underlying the complement system, which plays a crucial role in both acquired and innate immune responses. His major focus is on the GPI-linked complement regulatory protein, CD59. This protein serves to block a key step in the terminal phase of complement activation, namely, the formation of the membrane attack complex (MAC). The MAC is responsible for lysing the target cell harboring a foreign antigen but is prevented from lysing “self” tissues by negative regulators, such as CD59. He has generated mCD59 knockouts and human CD59 transgenic mice, investigating the role of CD59 in cardiovascular diseases and erythrocyte functions. He also focuses on developing anti-human CD59 inhibitor as a novel approach for the treatment of cancer, HIV-1, and HCV. His recent publications are listed in http://connects.catalyst.harvard.edu/profiles/profile/person/77253.
Biography Updated on 1 April 2012